Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder

Journal of Women's Health and Gender-Based Medicine

Volumn 11, Issue 2, 2002, Pages 95-96

  Megivern, Deborah ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; INSULIN; ORAL CONTRACEPTIVE AGENT; PLACEBO;

CLINICAL STUDY; CONTROLLED STUDY; DRUG FORMULATION; DRUG SCREENING; ENDOCRINE DISEASE; FEMALE; GENDER; HUMAN; INSULIN METABOLISM; LETTER; OVARY POLYCYSTIC DISEASE; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; PROVOCATION TEST; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; ENDOCRINE SYSTEM; MENTAL DISEASE;

CONTRACEPTIVES, ORAL; FEMALE; HUMANS; PATIENT SATISFACTION; PREMENSTRUAL SYNDROME; PROGESTERONE; TREATMENT OUTCOME;

EID: 0036213983     PISSN: 15246094     EISSN: None     Source Type: Journal    
DOI: 10.1089/152460902753645218     Document Type: Letter

References (7)

1. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder
2. Prevalence of mood and anxiety disorders in women who seek treatment for premenstrual syndrome
3. The dexamethasone suppression test and suicide prediction
4. Case study: Missed diagnosis and mistreatment of unrecognized comorbid Graves disease
5. When psychological disorders mask medical disorders: A guide for psychotherapists
6. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis